News

The United States Department of Justice originally filed the lawsuit in December 2021 on behalf of an elderly quadriplegic patient, alleging that Tempe, Arizona-based Barnet Dulaney Perkins Eye Center was requiring patients with mobility disabilities to hire third-party medical transport and transfer assistance for outpatient surgical procedures. American Vision Partners was named as a codefendant.

Researchers used obesity as a model to accelerate and exaggerate the stressors experienced by the body throughout life.

As a therapy for vision impairment resulting from inherited retinal degeneration, or IRD, the mRNA would instruct photoreceptor cells – faulty because of a genetic mutation – to manufacture the proteins needed for sight.

Researchers discovered that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Joshua Mali, MD, offers his top 5 prognostications for 2023.

According to researchers, factors that were associated with all type of visual impairment included older age, lower education level, and lower income were associated with all types of visual impairment.

In the study, investigators conducted a cross-sectional study with the goal of evaluating a correlation between the number of peer-reviewed publications published before a residency and the subsequent peer-reviewed publications or career choices of doctors who graduated from an ophthalmology residency program.

No treatment is currently available for the early stages of AMD, but some retrospective studies have reported an association between metformin and reduced risk of AMD.

To advance the company’s ability to anticipate on increasing patients’ needs and to pursue long-term growth plans in both fields of expertise, the company decided to spin out its retina division.

FT-001 is administered by a one-time injection into the subretinal space of the eye that delivers a functional copy of the human RPE65 gene to the nuclei of the patient’s retinal cells.

The investment supports the clinical development of two novel programs, both with the aim of being protective against vision loss.

Investigators concluded that both formulations of AR-1105 were well-tolerated and provided clinically meaningful and sustained visual improvements in vision and decreased retinal thickening despite that some patients had difficult-to-treat BRVO or CRVO with longstanding edema.

When dietary patterns were adjusted to include a Mediterranean diet, dietary nitrate intake was not associated with AMD progression independently.

The companies noted that the molecules selected are potent small molecules that work against well-validated therapeutic targets in retinal disease management, and that are designed to enable extended durability in the suprachoroidal space.

The investigators set out to determine how well ophthalmologists actually are represented when individuals conduct a Google search compared with their proportion in each U.S. county.

According to University of Michigan researchers, blinding eye diseases like macular degeneration, diabetic retinopathy, and glaucoma are accompanied by the death of neurons in the retina that leads to blindness.

According to a research team from the National Eye Institute, part of the National Institutes of Health, the technique provides model for studying genesis of age-related macular degeneration and other eye diseases.

The use of heavy silicone oil tamponade in secondary surgery for persistent full-thickness macular holes is a safe and efficient surgical method. Best-corrected visual acuity and minimum linear diameter before surgery may be indicators for anatomical success.

ROP is thought to be a two-stage disorder that begins with the arrested development of the retinal vessels in preterm babies when exposed to high oxygen levels at birth.

As 2022 draws to a close, it has proven to be a year of interesting developments in retina, and the top headlines of the year bear this out.

In a news release, Opus said it will advance preclinical development programs for BEST1– and RHO-related retinal diseases. The deal expands the company’s addressable patient population for its novel treatments for rare inherited retinal diseases.

The research team, led by Jayantha Gunaratne, PhD, senior principal investigator at IMCB, conducted a comprehensive analysis of the eye fluid samples from a well-defined cohort of proliferative DR patients against the control cohort to deduce impaired mechanistic aspects within the eye.

Korean biotech company MDimune Inc. and scientists from the Clear Vision Research Lab at The Australian National University hope to turn recent research milestones into potential treatments for AMD.

Derek Hodkey, president and CEO of Orbis International, discusses key achievements for the company and its Flying Eye Hospital in 2022 and offers his outlook for 2023.

The National Institute on Aging of the National Institutes of Health (NIH) is expanding the effort to understand that connection with a $10.3 million grant.

Steven J. Fliesler, PhD, has been named the 2022 recipient of the Retina Research Foundation’s (RRF) Paul Kayser International Award in Retina Research presented by the International Society for Eye Research (ISER).